<DOC>
	<DOCNO>NCT01765231</DOCNO>
	<brief_summary>The purpose study identify effect prophylactic entecavir HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patient lymphoma .</brief_summary>
	<brief_title>Prophylactic Use Entecavir HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma</brief_title>
	<detailed_description>The purpose study identify effect prophylactic entecavir HBsAg Negative/HBcAb Positive/hepatitis B virus DNA Negative patient lymphoma randomize entecavir prophylaxis group observation group . In entecavir prophylaxis group , entecavir 0.5 mg/day orally initiate day 1 first course antitumor therapy , continue least 6 month completion antitumor therapy . In observation group , entecavir 0.5mg daily prescribe patient hepatitis B virus reactivation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>treatmentnaive patient lymphoma HBsAg negative/HBcAb positive/hepatitis B virus DNA negative baseline treat chemotherapy and/or immunosuppressive therapy life expectancy 3 month young 18 year old HBsAg positive HBcAb negative hepatitis B virus DNA positive baseline pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Hepatitis B virus</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>